IntegraGen appoints Emmanuel Martin as Director for its new Genetic Research Services

Paris, France, 25 October 2006:  IntegraGen announced today the recent appointment of Emmanuel Martin as Director Sales and Marketing for its new business unit “Genetic Research Services”.

Customized high-throughput SNP genotyping services are provided to the research community to help accelerate discovery. IntegraGen offers access to the broadest technology portfolio in the market, including state-of-the art technologies such as SNPlex®, Agilent and Illumina® and IntegraChips™, superior BAC-arrays for genomic DNA applications.

Welcoming Emmanuel Martin in his new position, Dr Jan Mous, President and CEO of IntegraGen said: “Emmanuel has an outstanding track record and has already successfully brought in one major contract for genotyping. We are delighted to welcome him on board.”

Previously Mr. Martin worked at Applied Biosystems, Applera, France as a Senior Sales Specialist in SNP® genotyping and gene expression. In the eight years at Applied, he also worked as a business developer and research field engineer in Real Time PCR®. In addition Mr. Martin has over six years of research experience in molecular biology. He qualified as a pharmacist and received his DEA “Bases Fondamentales de l’Oncogénèse” from the University of Paris V, France.

Commenting on his new role at IntegraGen, Mr. Martin added: “IntegraGen is a very experienced company offering a lot of value to other researchers. I am delighted to take the lead on this new business unit and I am looking forward to the challenge of developing this outstanding expertise of the Company.”

Mr. Martin will be based at IntegraGen’s offices in Evry, near Paris and will be responsible for promoting IntegraGen’s genotyping services and for client and distributors relations.

- ENDS -

Notes to editors:

About IntegraGen

IntegraGen is a pioneer in the field of predictive healthcare. The Company is dedicated to discovering genes associated with complex diseases and commercializing molecular diagnostic tests to enable individualized diagnosis, prevention and treatment.

IntegraGen’s proprietary gene mapping technology GenomeHIP™ provides fast, reliable, and cost-effective discovery of genetic loci. Paired with strong biostatistics, bioinformatics and fine mapping genotyping capabilities, IntegraGen has successfully identified and patented genes associated with early and late onset diseases. Efforts are currently focus on Type-2 Diabetes, Obesity, Autism and Bi-Polar Disorder. Clinical trials for the company’s first diagnostics test, based on internally identified genes, are planned for Q1 2007.

IntegraGen has two commercial operations. Diagnostic testing and counselling services are offered through an ISO accredited Diabetes Competency Center, based in Bonn Germany. A Genetic Services business, operating out of the company headquarters in Evry, France, provides customized genotyping and BAC array services to the research community.

Founded in 2000, IntegraGen has 34 employees. IntegraGen is headquartered in Evry, near Paris. More information can be found at www.integragen.com 

For further information please contact:

At IntegraGen

Dr Jan Mous
CEO
Tel: +33 (0)1 60 91 09 00
Email: jan.mous@integragen.com

Northbank Communications

Sue Charles
CEO
Tel: +44 (0)20 3008 7562
s.charles@northbankcommunications.com

Dr Christelle Kerouedan
Account Manager
Tel: +44 (0)20 3008 7553
E-mail: c.kerouedan@northbankcommunications.com

Tony Stephenson
Account Manager (Media Relations)
Tel: +44 (0)20 3008 8787
E-mail: t.stephenson@northbankcommunications.com